Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib

China Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib, Find details about China Olaparib, Olaparib Powder from Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib

Model NO.
D-Sung Olaparib
Product Name
Olaparib
Name
Olaparib Powder
Appearance
White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anthelmintics
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
763113-22-0
Mf
C24h23fn4o3
Density
1.43
Refractive Index
1.702
MW
434.5
Trademark
D-Sung
Transport Package
Negotiable
Specification
99%
Origin
Xi′an Shaanxi
Model NO.
D-Sung Olaparib
Product Name
Olaparib
Name
Olaparib Powder
Appearance
White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anthelmintics
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
763113-22-0
Mf
C24h23fn4o3
Density
1.43
Refractive Index
1.702
MW
434.5
Trademark
D-Sung
Transport Package
Negotiable
Specification
99%
Origin
Xi′an Shaanxi
Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib
Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib
Product Description

Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib

Product Details

Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib

Product NameOlaparib
AppearanceWhite Power
CAS No.763113-22-0
MFC24H23FN4O3
Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.
Application&Function

Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibOlaparib is an anti-tumor targeted therapy drug, which kills cancer cells mainly by synthesizing a lethal mechanism. It is mainly used clinically for the treatment of advanced epithelial ovarian cancer.
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

Specification

Antineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical OlaparibAntineoplastic CAS 763113-22-0 Olaparib Anti-Cancer Powder Olaparib Pharmaceutical Olaparib